**Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis**

<table>
<thead>
<tr>
<th>Medical Benefit</th>
<th>Effective Date: 04/01/15</th>
<th>Next Review Date: 11/20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preauthorization</td>
<td>No</td>
<td>Review Dates: 07/07, 07/08, 11/08, 05/09, 01/10, 01/11, 01/12, 03/12, 01/13, 01/14, 11/14, 11/15, 11/16, 11/17, 11/18, 11/19</td>
</tr>
</tbody>
</table>

*Preauthorization is not required.*

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

**Populations**
- Individuals: With chronic rhinosinusitis

**Interventions**
- Interventions of interest are:
  - Balloon ostial dilation as a stand-alone procedure

**Comparators**
- Comparators of interest are:
  - Medical management
  - Functional endoscopic sinus surgery

**Outcomes**
- Relevant outcomes include:
  - Symptoms
  - Change in disease status
  - Quality of life
  - Treatment-related morbidity

**DESCRIPTION**

Balloon ostial dilation (also known as balloon sinuplasty) is proposed as an alternative to traditional endoscopic sinus surgery (ESS) for patients with chronic rhinosinusitis who fail medical management. The procedure involves placing a balloon in the sinus ostium and inflating the balloon to stretch the opening. It can be performed as a stand-alone procedure or as an adjunctive procedure to functional endoscopic sinus surgery (FESS).

**SUMMARY OF EVIDENCE**

For individuals with chronic rhinosinusitis who receive balloon ostial dilation as a stand-alone procedure, the evidence includes systematic reviews and RCTs. Relevant outcomes are symptoms, change in disease status, quality of life, and treatment-related morbidity. The available systematic reviews (including a Cochrane review and a TEC Assessment) concluded that, although nonrandomized evidence has suggested balloon ostial dilation has similar outcomes to FESS, evidence from randomized trials is needed to demonstrate an improvement in outcomes for patients treated with balloon ostial dilation. Since the publication of those systematic reviews, the REMODEL RCT has been published. It assessed 105 patients, reporting comparable symptom improvement from six months through 18 months in patients with chronic maxillary sinusitis who received balloon ostial dilation or FESS. Lower rates of postoperative debridement to remove clots and scar tissue were found in the balloon treated patients. Balloon ostial dilation can be performed with local anesthesia in the office setting. Limitations of the REMODEL trial included its unblinded outcomes assessment and differential dropout between groups. Other trials have provided limited additional evidence. Clinical vetting suggests that balloon ostial dilation is an acceptable alternative to FESS in selected patients. Therefore the evidence is sufficient to determine the effects of the technology on health outcomes.
POLICY

Use of a catheter-based inflatable device (balloon ostial dilation) in the treatment of medically refractory chronic sinusitis may be considered medically necessary as a minimally invasive alternative to endoscopic sinus surgery.

BACKGROUND

CHRONIC RHINOSINUSITIS

Chronic rhinosinusitis (CRS) is characterized by purulent nasal discharge, usually without fever, that persists for weeks to months. Symptoms of congestion often accompany the nasal discharge. There also may be mild pain and/or a headache. Thickening of mucosa may restrict or close natural openings between sinus cavities and the nasal fossae, although symptoms vary considerably because of the location and shape of these sinus ostia.

Treatment

Estimates have suggested approximately 30 million individuals in the United States suffer from CRS. Most cases are treated with medical therapy, but surgical drainage is an option for patients who fail to respond to medical therapy. Functional endoscopic sinus surgery (FESS) has become an important aspect for surgical management of chronic sinusitis, although evidence from randomized controlled trials is limited. For this procedure, a fiberoptic nasal endoscope is used to visualize the sinus ostia, and any obstruction found is corrected. This procedure restores patency and allows air and mucous transport through the natural ostium. Approximately 350,000 FESS procedures are done each year in the United States for CRS.

A newer procedure, balloon ostial dilatation can be used as an alternative or as an adjunct to FESS for those with CRS. The goal of this technique, when used as an alternative to FESS, is to improve sinus drainage using a less invasive approach. When used as an adjunct to FESS, it is intended to facilitate and/or increase access to the sinuses. The procedure involves placing a guidewire in the sinus ostium, advancing a balloon over the guidewire, and then stretching the opening by inflating the balloon. The guidewire location is confirmed with fluoroscopy or with direct trans-illumination of the targeted sinus cavity. General anesthesia may be needed for this procedure to minimize patient movement.

The maxillary sinus creates a unique challenge. The maxillary ostia, located within the ethmoid infundibulum, often cannot be accessed transnasally without excising a portion of the uncinate process. An alternative approach to the maxillary ostia is through the sinus, via the canine fossa. A guidewire can be advanced from within the maxillary sinus to the nasal fossa. The dilating balloon can enlarge the ostia while deflecting the uncinate process.

Outcomes

To quantify the severity of CRS and to assess treatment response, various outcomes measures can be used, including radiologic scores, endoscopic grading, and patient-reported quality of life (QOL) measures.

The Lund-Mackay scoring system uses radiologist-rated information derived from computed tomography scans to assess opacification of the sinus cavities, generating a score from 0 to 12.1,2 Disease-specific patient-reported QOL scores include the commonly used Sino-Nasal Outcome Test-20 (SNOT-20), which is a validated questionnaire for which patients complete 20 symptom questions on a categorical scale (0 [no bother] to 5 [worst symptoms can be]). Average rankings can be reported over all 20 symptoms, as well as by FOUR subclassified symptom domains. The SNOT-22, a variation of the SNOT-20, includes two additional questions (on “nasal obstruction” and “loss of smell and taste”). The minimal clinically important difference for the SNOT-22 has been estimated to be 8.9 points.3
Additionally, QOL has been reported using overall health-related QOL scores, such as the 36-Item Short-Form Health Survey. That tool includes eight scaled scores on various health domains, which are transformed into a 0-to-100 scale (100 corresponding to best health).

REGULATORY STATUS

In 2008, the Relieva™ Sinus Balloon Catheter (Acclarent, Menlo Park, CA) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. FDA determined that this device was substantially equivalent to existing devices for use in dilating the sinus ostia and paranasal spaces in adults and maxillary sinus spaces in children. Subsequent devices developed by Acclarent have also been cleared by FDA through the 510(k) process. They include the Relieva Spin Sinus Dilation System® (cleared in 2011) and the Relieva Seeker Balloon Sinuplasty System® (cleared in 2012).

In 2008, the FinESS™ Sinus Treatment (Entellus Medical, Maple Grove, MN) was cleared for marketing by FDA through the 510(k) process. The indication noted is to access and treat the maxillary ostia/ethmoid infundibulum in adults using a transantral approach (FDA product code: EOB). The bony sinus outflow tracts are remodeled by balloon displacement of adjacent bone and paranasal sinus structures. Two other balloon sinus ostial dilation devices, the ENTrigue® Sinus Dilation System (ENTrigue Surgical, acquired by more recently by Smith & Nephew), and the XprESS™ Multi-Sinus Dilation Tool, also received 510(k) clearance in 2012.

In 2013, a sinus dilation system (Medtronic Xomed, Jacksonville, Fl), later named the NuVent™ EM Balloon Sinus Dilation System, was cleared for marketing by FDA through the 510(k) process for use in conjunction with a Medtronic computer-assisted surgery system when surgical navigation or image-guided surgery may be necessary to locate and move tissue, bone, or cartilaginous tissue surrounding the drainage pathways of the frontal, maxillary, or sphenoid sinuses.

Also in 2013, a sinus dilation system (Smith & Nephew), later named the Ventera™ Sinus Dilation System, was cleared for marketing through the 510(k) process to access and treat the frontal recesses, sphenoid sinus ostia, and maxillary ostia/ethmoid infundibula in adults using a transnasal approach.

Table 1 summarizes the currently FDA cleared balloon sinus dilation devices.

FDA product code: LRC.

Table 1. Balloon Ostial Dilation Devices Cleared by the U.S. Food and Drug Administration

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>510(k) No.</th>
<th>Date Cleared</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>MESIRE - Balloon Sinus Dilatation System</td>
<td>Meril Life Sciences</td>
<td>K172737</td>
<td>12/12/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva SpinPlus Nav Balloon Sinuplasty System</td>
<td>Acclarent Inc.</td>
<td>K171687</td>
<td>9/5/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS ENT Dilation System</td>
<td>Entellus Medical Inc.</td>
<td>K163509</td>
<td>4/5/2017</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva UltirraNav Sinus Balloon Catheter</td>
<td>Acclarent Inc.</td>
<td>K161698</td>
<td>10/24/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Vent-Os Sinus Dilation Family</td>
<td>Sinusys Corp.</td>
<td>K160770</td>
<td>6/29/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva Scout Multi-Sinus Dilation System</td>
<td>Acclarent Inc.</td>
<td>K153341</td>
<td>2/12/2016</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS Multi-Sinus Dilation System</td>
<td>Entellus Medical Inc.</td>
<td>K152434</td>
<td>11/20/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>DSS Sinusplasty Balloon Catheter</td>
<td>Intuit Medical Products LLC</td>
<td>K143738</td>
<td>8/27/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>Relieva SpinPlus Balloon Sinuplasty System</td>
<td>Acclarent Inc.</td>
<td>K143541</td>
<td>4/22/2015</td>
<td>Sinus Ostia Dilation</td>
</tr>
<tr>
<td>XprESS Multi-Sinus Dilation Tool</td>
<td>Entellus Medical Inc.</td>
<td>K142252</td>
<td>10/17/2014</td>
<td>Sinus Ostia Dilation</td>
</tr>
</tbody>
</table>
RELATED PROTOCOL
Steroid-Eluting Sinus Stents

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.